Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University
Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry...
Read moreLatest News
Category: ASX
Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry...
Read moreTelix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with...
Read moreTelix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging...
Read moreTelix Pharmaceuticals provides notice of The Annual General Meeting of the Shareholders on Tuesday 12 May...
Read moreTelix Pharmaceuticals (U.S.) Inc. is pleased to announce it has entered into a commercial agreement with Cardinal...
Read moreTelix is pleased to announce it has now completed the acquisition of a licensed radiopharmaceutical production facility in Seneffe,...
Read moreTelix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer...
Read moreTelix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its submission of an NDA for...
Read moreTelix Pharmaceuticals Limited Releases Annual Report Year Ending...
Read moreTelix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s...
Read more